Virax Biolabs
VRAX
7 hedge funds and large institutions have $81.8K invested in Virax Biolabs in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
553% more capital invested
Capital invested by funds: $12.5K → $81.8K (+$69.3K)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
133% more funds holding
Funds holding: 3 → 7 (+4)
0.09% more ownership
Funds ownership: 0.03% → 0.12% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$27.8K |
| 2 |
HF
HRT Financial
New York
|
+$25.4K |
| 3 |
Renaissance Technologies
New York
|
+$10.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$297 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$10.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $33K | +$27.8K | +1,122 | New |
|
|
HF
2
HRT Financial
New York
| $29K | +$25.4K | +1,027 | New |
|
|
3
Renaissance Technologies
New York
| $12.8K | +$10.9K | +440 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $6.5K | +$3K | +121 | +117% |
|
|
5
Qube Research & Technologies (QRT)
London,
United Kingdom
| $348 | +$297 | +12 | New |
|
6
Wells Fargo
San Francisco,
California
| $116 | – | – | – |
|
|
HT
7
Headlands Technologies
Chicago,
Illinois
| $52 | +$50 | +2 | New |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$10.6K | -591 | Closed |
|
VRAX Hedge Fund Activity: Q2 2024 in Review
7 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q2 2024, worth a combined $81.8K — up 553% from $12.5K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VRAX positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $27.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $10.6K sold.
- 7 institutional investors held Virax Biolabs (VRAX) as of Q2 2024, up from 3 in Q1 2024.
- Funds reported $81.8K of Virax Biolabs stock for Q2 2024, up 553% quarter-over-quarter.
- 5 funds opened new Virax Biolabs positions in Q2 2024 and 1 closed out, a net change of +4 holders.
- The largest Virax Biolabs buyer in Q2 2024 was Virtu Financial, an estimated $27.8K added.
- The largest Virax Biolabs seller in Q2 2024 was Citadel Advisors, an estimated $10.6K sold.
Based on aggregated 13F filings for Q2 2024.